CRM revenue expected to fall to 10% of total by 2030
Veeva reported strong Q4 and FY2026 results, beating expectations. Management discussed the accelerating migration from legacy CRM systems, and the synergistic opportunity with LLM providers like Anthropic and OpenAI in building AI agents for life sciences. Guidance for FY2027 is 13% revenue growth. Total FY2026 revenue was $3.195B, with Q4 revenue of $836M.
Buzzberg 분석CRM revenue expected to fall to 10% of total by 2030Veeva reported strong Q4 and FY2026 results, beating expectations. Management discussed the accelerating migration from legacy CRM systems, and the synergistic opportunity with LLM providers like Anthropic and OpenAI in building AI agents for life sciences. Guidance for FY2027 is 13% revenue growth. Total FY2026 revenue was $3.195B, with Q4 revenue of $836M.전체 분석 보기분석 접기
Veeva reported strong Q4 and FY2026 results, beating expectations. Management discussed the accelerating migration from legacy CRM systems, and the synergistic opportunity with LLM providers like Anthropic and OpenAI in building AI agents for life sciences. Guidance for FY2027 is 13% revenue growth. Total FY2026 revenue was $3.195B, with Q4 revenue of $836M.
Veeva is aggressively migrating customers to Vault CRM, with 140+ live and a high win rate predicted outside the top 20.
The end-of-support date for legacy Veeva CRM was pulled forward to Dec 2029, reflecting strong Vault CRM momentum.
Management sees AI as a symbiotic opportunity with LLM providers, with a focus on integrating AI agents to address the biggest bottleneck in life sciences value.
Revenue$0.836B
+3% QoQ
EPS$2.06
+1% QoQ
Gross margin74.46%
reported
Op margin29.41%
reported
이번 분기에 달라진 점
01
Guidance
CRM revenue expected to fall to 10% of total by 2030
Guidance tone
02
Demand
Vault CRM live customers near 140, top 20 wins solid
Management expressed confidence in strong execution, product momentum (e.g., Vault CRM live customers, top 20 wins), and a clear long-term vision for AI, while acknowledging execution risks and early monetization.
03
AI
AI token-based pricing model, not material in FY27
AI is a driver but not a major one yet; management sees strong customer interest and a right to win in tightly integrated AI applications, with early ROI in commercial content and agentic CRM, though monetization will not be material in FY27.
04
Demand
RTSM top 20 win is milestone, long ramp
Vault CRM live customers near 140, top 20 wins solid. Management expressed confidence in strong execution, product momentum (e.g., Vault CRM live customers, top 20 wins), and a clear long-term vision for AI, while acknowledging execution risks and early monetization.
AI, 자본지출 및 수요 분석
AI
플랫폼 및 수익화
AI is a driver but not a major one yet; management sees strong customer interest and a right to win in tightly integrated AI applications, with early ROI in commercial content and agentic CRM, though monetization will not be material in FY27.
수요
수주 및 전환
Vault CRM live customers near 140, top 20 wins solid. Management expressed confidence in strong execution, product momentum (e.g., Vault CRM live customers, top 20 wins), and a clear long-term vision for AI, while acknowledging execution risks and early monetization.
톤 · Confident
Management expressed confidence in strong execution, product momentum (e.g., Vault CRM live customers, top 20 wins), and a clear long-term vision for AI, while acknowledging execution risks and early monetization.
병목
Manufacturing capacity
There's a lot of focus on that, and yes, that'll get faster, but that's not the real bottleneck.
“There's a lot of focus on that, and yes, that'll get faster, but that's not the real bottleneck.”
Veeva is accelerating the end-of-support date for its legacy CRM product by 9 months to December 2029, signaling faster-than-expected industry migration and stronger Vault CRM traction.
“We moved the date to December of 29. It used to be roughly September of 2030. So we pulled it in about eight or nine months. The reason we did that is one is Vault CRM is going well.”
Veeva's focus on agentic AI and data integration with AI doctors/large language models could help address a key 90% value loss in life sciences, potentially expanding the pharma market.
Okay, great. Thanks, Peter. On CRM, Brian made, I thought, interesting comments at a January conference around how that business is going to become about 10% of Viva in 2030, so call it a $600 million run rate. I think that's a bigger number than many would have penciled in at the start of events and transitions happening there. Are there things like service center or campaign managers that are adding incrementally to the forecast? And how would you think about those increments rolling in versus the timing of what you know will roll off in probably that 28 and 29 timeframe?
I'll just put a few puts and takes on that. The add-on products, you know, patient CRM, service center, campaign manager, those can grow. And also, there's some puts and takes in the course here. So, you know, a couple of the large top 20s, for example, were on IQVIA. Okay, those are going on over to Viva. We didn't have those before. Some med tech companies, yes, and Salesforce is getting a few of those as well. So there's puts and there's, we might focus on the takes, which, but there's puts and takes in that area, and then the add-ons will grow.
Veeva is accelerating the end-of-support date for its legacy CRM product by 9 months to December 2029, signaling faster-than-expected industry migration and stronger Vault CRM traction. — A faster end-of-support deadline will force more Salesforce CRM users to make migration decisions sooner, potentially accelerating Veeva's market share gains and impacting Salesforce's remaining pharma CRM revenue.
Veeva's focus on agentic AI and data integration with AI doctors/large language models could help address a key 90% value loss in life sciences, potentially expanding the pharma market. — If Veeva successfully connects its software to AI-driven patient care, it could help improve patient outcomes and increase the total addressable market for its customers.